# Intercell

> Mediated Wiki article. Canonical URL: https://mediated.wiki/source/Intercell
> Markdown URL: https://mediated.wiki/source/Intercell.md
> Source: https://en.wikipedia.org/wiki/Intercell
> Source revision: 1213538582
> License: Creative Commons Attribution-ShareAlike 4.0 International (https://creativecommons.org/licenses/by-sa/4.0/)

**Intercell AG** was a biotechnology company based in [Vienna](/source/Vienna) which focused on the development of modern prophylactic and [therapeutic vaccines](/source/Therapeutic_vaccines) against infectious diseases. The company merged with Vivalis to form [Valneva SE](/source/Valneva_SE) in 2012.[2] Intercell was formed in 1998 as a [spin-off](/source/Research_spin-off) of the [Research Institute of Molecular Pathology](/source/Research_Institute_of_Molecular_Pathology) (IMP) in Vienna.[3] It employs 400 people in Austria, Scotland and the United States.

## History

It was founded in 1998 and focused on the research, development, and commercialization of vaccines and other biological products. Intercell AG's products were used to prevent and treat a variety of infectious diseases, including hepatitis B, Japanese encephalitis, and pneumonia. In 2012, Intercell AG merged with Vivalis SE, a French biotech company, to form [Valneva](/source/Valneva).[4]

It has been listed on the [Vienna Stock Exchange](/source/Vienna_Stock_Exchange) since February 28, 2005. In 2008, Intercell signaled its intent to acquire [Maryland](/source/Maryland)-based [Iomai](/source/Iomai), a developer of needle-free vaccination technology.[5][6]

Intercell cooperates with [pharmaceutical companies](/source/Pharmaceutical_company) like [Novartis](/source/Novartis), [Merck](/source/Merck_%26_Co.) and [Sanofi-Aventis](/source/Sanofi-Aventis) on vaccine production.

The most important projects of Intercell are:

- Vaccine against [Japanese encephalitis](/source/Japanese_encephalitis) (approved in Europe, America and Australia)[7][8][9]

- Therapeutic vaccine against [hepatitis C](/source/Hepatitis_C) (in clinical [phase II](/source/Clinical_trial#Phase_II))[10]
- [Antigen](/source/Antigen) identification program and [adjuvant](/source/Adjuvant) technologies.
- Vaccine Enhancement Patch to improve prevention against pandemic [influenza](/source/Influenza) (in collaboration with [U.S. Department of Health and Human Services](/source/United_States_Department_of_Health_and_Human_Services), in clinical phase II)

## References

1. ["Annual Report 2010"](https://web.archive.org/web/20110626181045/http://www.intercell.com/uploads/media/2010_Annual_Report.pdf). Intercell. Archived from [the original](http://www.intercell.com/uploads/media/2010_Annual_Report.pdf) on 26 June 2011. Retrieved 3 May 2011.

1. Carroll, John (17 December 2012). ["Troubled Intercell throws in the towel, signs off on merger deal with Vivalis"](https://www.fiercebiotech.com/financials/troubled-intercell-throws-towel-signs-off-on-merger-deal-vivalis). Fierce Biotech. Retrieved 27 January 2018.

1. ["Research Institute of Molecular Pathology (IMP) - About the IMP > History"](http://www.imp.ac.at/about-the-imp/history/). Research Institute of Molecular Pathology. Retrieved 2009-07-25. [dead link]

1. ["The Dark Horse of the Vaccine Race May Be This French Biotech"](https://www.bloomberg.com/news/articles/2021-04-29/a-french-biotech-says-inactivated-vaccines-are-the-way-to-fight-covid-variants). *Bloomberg.com*. 2021-04-29. Retrieved 2023-01-09.

1. Fox, Maggie & Grenon, Andre (2008-05-12). ["Austrian vaccine maker Intercell buys Iomai"](https://www.reuters.com/article/idUSN1233533220080512). Reuters. [Archived](https://web.archive.org/web/20110620190251/http://www.reuters.com/article/idUSN1233533220080512) 2011-06-20 at the Wayback Machine. Retrieved 2008-08-15.

1. Staff (1 June 2008), "Intercell to Acquire Iomai for $189M", *Genetic Engineering & Biotechnology News*. Vol. 28, no. 11, News: Inside Industry, Mary Ann Liebert, Inc., p. 14, [ISSN 1935-472X](https://www.worldcat.org/issn/1935-472X)

1. ["Intercell's Japanese Encephalitis Vaccine FDA approval"](http://www.intercell.com/main/forbeginners/news/not-in-menu/news-full/browse/1/back_to/news/article/intercell-announces-fda-approval-of-ixiaroR-a-vaccine-against-japanese-encephalitis-a-successf/). Medical News Today. 2009-03-31. Retrieved 2009-03-31. [dead link]

1. ["Intercell's Japanese Encephalitis Vaccine EMEA approval for Europe"](http://www.intercell.com/main/forbeginners/news/not-in-menu/news-full/browse/1/back_to/news/article/intercell-announces-european-approval-of-new-vaccine-ixiaroR-to-prevent-japanese-encephalitis/). Intercell. 2009-04-02. Retrieved 2009-04-02. [dead link]

1. ["Intercell's Japanese Encephalitis Vaccine Australian TGA approval"](http://www.intercell.com/main/forbeginners/news/not-in-menu/news-full/browse/2/back_to/news/article/australian-authorities-tga-first-to-grant-final-product-approval-for-intercells-vaccine-to-preven/). Intercell. 2009-01-23. Retrieved 2009-01-23. [dead link]

1. ["Intercell Hepatitis C Vaccine Meets Primary Endpoints"](http://www.fdanews.com/newsletter/article?articleId=97461&issueId=10614). FDA News. 2007-08-22. Retrieved 2008-08-15.

## External links

- [Official website](http://www.intercell.com/)

---
Adapted from the Wikipedia article [Intercell](https://en.wikipedia.org/wiki/Intercell) by Wikipedia contributors ([contributor history](https://en.wikipedia.org/wiki/Intercell?action=history)). Available under [Creative Commons Attribution-ShareAlike 4.0 International](https://creativecommons.org/licenses/by-sa/4.0/). Changes may have been made.